<DOC>
	<DOCNO>NCT03065816</DOCNO>
	<brief_summary>Primary Objective : Pharmacodynamics : assessment comparison gamma scintigraphy gastric retention alginate raft ( raft performance ) Z0063 effect Gaviscon Double Action Tablets , healthy adult subject . Secondary Objective : Safety : assessment clinical safety Z0063 versus Gaviscon Double Action tablet , healthy adult subject .</brief_summary>
	<brief_title>Scintigraphy Study Compare Antireflux Activity Z0063 Versus Gaviscon Double Action Tablets , Healthy Adult Subjects</brief_title>
	<detailed_description>The total study duration per subject 37 day include screening period 21 day , wash-out period 4-7 day follow-up 4-7 day .</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Alginate , aluminium hydroxide , magnesium trisilicate , sodium bicarbonate drug combination</mesh_term>
	<mesh_term>Almagate</mesh_term>
	<mesh_term>Aluminum Hydroxide</mesh_term>
	<mesh_term>Magnesium Hydroxide</mesh_term>
	<criteria>Inclusion criterion : Male female subject , 18 55 year age , inclusive . Body weight 50.0 100.0 kg , inclusive , male , 40.0 90.0 kg , inclusive , female , body mass index 18.0 28.0 kg/m^2 , inclusive . Certified healthy comprehensive clinical assessment . Normal vital sign , electrocardiogram ( ECG ) laboratory parameter . Subject willing eat standard radiolabelled meal ( eggs toast orange juice ) . Exclusion criterion : Any history presence clinically relevant abnormality screen could interfere objective study safety subject 's participation . Blood donation 450 mL within 3 month inclusion . History presence drug alcohol abuse . Smoking 5 cigarette equivalent per day , unable stop smoking study . If female , pregnancy ( define positive betahuman chorionic gonadotropin [ Î²HCG ] blood test ) , breastfeed . Any medication ( include St John 's Wort ) within 14 day inclusion exception hormonal contraception menopausal hormone replacement therapy . Any subject exclusion period previous study : participation new chemical entity clinical study within previous 3 month market drug clinical study within previous 30 day . Any subject contact case emergency . Positive result follow test : hepatitis B surface ( HBs Ag ) antigen , antihepatitis C virus ( antiHCV ) antibody , antihuman immunodeficiency virus 1 2 antibody ( antiHIV1 anti HIV2 Ab ) . Positive result urine drug screen . Positive alcohol test . Known hypersensitive alginates , product formulation excipients and/or component standardize meal . Any subject difficulty chew and/or swallowing . Participation study radioisotope administer subject expose radiation normal background radiation within 12 month screen visit . Any intake aluminum magnesium contain antacid alginatecontaining medicinal product within 14 day inclusion . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>